BlackRock Japan’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

BlackRock Japan’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-492	Closed	-$5K	–	1558
2016 Q1	$5K	Sell	492 -36	-7%	-$715	﹤0.01%	1364
2015 Q4	$16K	Sell	528 -23	-4%	-$695	﹤0.01%	1207
2015 Q3	$17K	Buy	+551	New	+$26.4K	﹤0.01%	1116

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

BlackRock Japan's PTX Position: Q2 2016 in Review

BlackRock Japan sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 492 shares — an estimated $5K sold.

BlackRock Japan first reported a position in PTX in Q3 2015 and held it in 3 quarters. The position peaked at $17K in Q3 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

BlackRock Japan reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
BlackRock Japan sold 492 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $5K.
BlackRock Japan first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2015 and held it in 3 quarters.
BlackRock Japan's Pernix Therapeutics Holdings, Inc. position peaked at $17K in Q3 2015.
56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on BlackRock Japan's 13F filing for Q2 2016, filed 10 Aug 2016.